The Dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, medical devices, pharmaceuticals, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.

A roundup of recent medtech mergers & acquisitions, strategic alliances, and financings.

Inhibikase Therapeutics, a creator of anti-infective therapies, has elected Dr Steven Gilman to its board of directors. Dr Gilman currently serves as executive vice-president, R&D and chief scientific officer at Cubist Pharmaceuticals. Prior to this, he was chairman, president and CEO of ActivBiotics.

VCs see rich exit opportunities, especially for start-ups with multiple products in their pipelines. In this issue we profile four emerging antibiotic drug developers: Cempra Pharmaceuticals, DesignMedix, Kenta Biotech and MGB Biopharma.